Arcus Biosciences
RCUS
148 hedge funds and large institutions have $1.16B invested in Arcus Biosciences in 2020 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 41 increasing their positions, 51 reducing their positions, and 18 closing their positions.
111% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 18
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
61% more call options, than puts
Call options by funds: $6.8M | Put options by funds: $4.22M
52% more capital invested
Capital invested by funds: $761M → $1.16B (+$397M)
16% more funds holding
Funds holding: 128 → 148 (+20)
0.3% more ownership
Funds ownership: 68.39% → 68.69% (+0.3%)
20% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$33.3M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$20.2M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$9.38M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$9.34M |
| 5 |
Goldman Sachs
New York
|
+$7.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$16.8M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$13.4M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$9.43M |
| 4 |
Two Sigma Investments
New York
|
-$9.38M |
| 5 |
Alkeon Capital Management
New York
|
-$7.45M |
RCUS Hedge Fund Activity: Q4 2020 in Review
148 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q4 2020, worth a combined $1.16B — up 52% from $761M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new RCUS positions and 18 closed out — a net gain of 20 holders — while 41 added to existing stakes and 51 trimmed.
The largest buyer was Ameriprise, opening a new position worth an estimated $33.3M. The largest seller was State Street, cutting an estimated $16.8M.
- 148 institutional investors held Arcus Biosciences (RCUS) as of Q4 2020, up from 128 in Q3 2020.
- Funds reported $1.16B of Arcus Biosciences stock for Q4 2020, up 52% quarter-over-quarter.
- 38 funds opened new Arcus Biosciences positions in Q4 2020 and 18 closed out, a net change of +20 holders.
- The largest Arcus Biosciences buyer in Q4 2020 was Ameriprise, an estimated $33.3M added.
- The largest Arcus Biosciences seller in Q4 2020 was State Street, an estimated $16.8M sold.
Based on aggregated 13F filings for Q4 2020.